Autoimmune Hepatitis at ACG 2023, with Gina Choi, MD

Episode Highlights0:12 Intro1:24 Challenges in autoimmune hepatitis3:30 Patient demographics4:25 Diagnostic challenges6:35 What is overlap syndrome?8:04 Mysteries behind immune dysregulation9:05 Promising drugs in investigation10:51 The BAFF receptor target11:41 Infliximab & rituximab12:38 An autoimmune hepatitis wishlist15:29 OutroAutoimmune hepatitis (AIH), a rare liver disease characterized by an unclear driver of inflammation, is historically challenged by limited clinical understanding, a slow development of treatment options in investigation, and a nonetheless concerning prognosis for affected adults and children.While some prospects are in development to aid specialists in adequately identifying risk factors for, diagnosing and treating AIH, education and communication on those developments is vital.In an interview with HCPLive during the American College of Gastroenterology (ACG 2023) Annual Scientific Meeting in Vancouver, BC this week, Gina Choi, MD, associator clinical professor of medicine and surgery at UCLA Health, discussed the ins and outs of modern autoimmune liver disease research and development. Including the treatment pipeline and current standards for diagnostics, Choi additionally discussed the sociodemographic and pathophysiological traits of AIH burden—as well as the lesser-known overlap syndrome.For more hepatology and gastroenterology coverage from ACG 2023, visit us at https://www.hcplive.com/conference/acg.